R&D News | pharmaphorum

News

SonoThera's $125m Series B heads recent biofinancings

Our latest roundup of financings in the biotech sector includes impressive rounds for SonoThera, Ethyreal, CeQur, and City Therapeutics.

News

Cancer biotech Parabilis books record IPO, raising $670m

Parabilis has broken the IPO record set by Kailera in April, packing its coffers as it starts an ambitious trial programme for lead drug zolucatetide.

News

Stop sign with green fields in the background

Sanofi abandons phase 3 trial of neurology drug riliprubart

Sanofi's neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart in rare disease CIDP was stopped for futility.

News

Moderna Innovation and Technology Centre

Moderna jab on trial for cancer-causing syndrome

Patients with Lynch syndrome could have a potential treatment on the horizon, as a Moderna mRNA vaccine starts trials at Oxford University.

News

ADA: AZ reveals oral GLP-1 data in obesity, diabetes

AstraZeneca prepares to move its oral GLP-1 elecoglipron into phase 3 for obesity and diabetes, after reporting encouraging phase 2b data at ADA.

News

GSK pursues $10.6bn takeover of cancer biotech Nuvalent

GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.

SonoThera's $125m Series B heads recent biofinancings

Cancer biotech Parabilis books record IPO, raising $670m

Sanofi abandons phase 3 trial of neurology drug riliprubart

Moderna jab on trial for cancer-causing syndrome

ADA: AZ reveals oral GLP-1 data in obesity, diabetes

GSK pursues $10.6bn takeover of cancer biotech Nuvalent

ASCO 2026: All about DNA damage response, with Luke Piggot

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks